Through licensing agreements and plant-based production, Serendip combines its plant-derived nanotechnology with partners’ therapeutic compounds to improve efficacy, tolerance, and production costs. This non-viral, thermostable, and naturally low-immunogenic carrier (also called vector) can transport proteins, peptides, and RNA while enabling precise molecular and cellular targeting. For the next generation of therapeutics, Serendip’s technology offers a safe, efficient, and scalable delivery platform. Proof of Concepts are being generated with antigens, cytotoxic and immuno-stimulant molecules.